Shots:

• The US FDA has issued a complete response letter for the NDA of filgotinib to treat moderately to severely active RA. FDA has requested data from two ongoing clinical trials- MANTA and MANTA-Ray assessing the effect of filgotinib (200mg) on sperm parameter
• The authority has expressed concerns regarding the overall benefit/risk profile of the filgotinib (200mg). The company will evaluate the points raised in the CRL for discussion with the FDA and will continue to believe in the results of P-III FINCH clinical program
• The company anticipates the study of MANTA and MANTA-RAy studies in H1’21. Filgotinib is currently under review by regulatory authorities across the globe and has received the CHMP’s positive opinion- recommending MAA for filgotinib in the EU to treat mod. to sev. RA who have responded inadequately or are intolerant to one or more disease-modifying anti-rheumatic drugs

Click here ­to­ read full press release/ article 

Ref: Gilead | Image: Gilead